+91-8668442535

Autoimmune Diseases Treatment Market By Type (Chemical-based Drugs, Biological Drugs) - Growth, Share, Opportunities & Competitive Analysis, 2016 - 2022

This report on the global autoimmune diseases treatment market studies various drugs used for treating autoimmune diseases along with pipeline analysis of upcoming potential drugs. Autoimmune diseases (A.D.s) are a family of more than 80 chronic and often disabling illnesses broadly characterized by immune system dysfunction leading to the loss of tolerance to self-antigens, presence of increased level of autoantibodies, inflammatory and mediatory cells, and resulting chronic inflammation. Thus, the autoimmune diseases treatment market’s drug pipeline comprises potential more target-specific drugs with innovative properties. 

For this study, the various therapeutic types studied include chemical-based drugs and biological drugs; further, chemical-based drugs are segmented as immunosuppressant drugs, NSAIDs, and corticosteroids. Market size estimates and forecasts for these segments for 2013 to 2022 are provided in terms of USD Mn and the respective CAGRs for 2016 to 2022, considering 2015 as the base year.

The pipeline analysis for the autoimmune diseases treatment market comprises projected market sales of Phase III drugs estimated till 2022. There are more than 80 types of clinically different autoimmune diseases. Some common autoimmune diseases are Hashimoto’s thyroiditis, type I diabetes, Crohn’s disease, multiple sclerosis, rheumatoid arthritis, ankylosing spondylitis systemic lupus erythematosus, and psoriasis. Therefore, we have estimated sales of very specific molecules based on the type (chemical-based or biological), disease prevalence, sponsor, peak sales by leading market experts, and other factors.

The geographic segmentation of the global autoimmune diseases treatment market is performed for the regions of North America, Europe, Asia Pacific, and the Rest of the World markets. The regions are also further sub-segmented on the basis of major countries. Market size estimates and forecasts for these segments for 2013 to 2022 are provided in terms of USD Mn, along with the respective CAGRs for the period 2016 to 2022, considering 2015 as the base year.

According to the American Autoimmune Related Diseases Association (AARDA), autoimmune disease affects up to 50 million Americans. The leading autoimmune disorders are type I diabetes mellitus, Grave’s, inflammatory bowel disease, multiple sclerosis, psoriasis, rheumatoid arthritis, and systemic lupus erythematosus. Autoimmune diseases are expected to be among the top 10 causes of death in women under the age of 65 and the second highest cause of chronic illness. Further, it is observed as the top cause of morbidity in women in the U.S.

Based on the therapeutics type, the autoimmune diseases treatment market is segmented into:

  • Chemical-based Drugs
  • Immunosuppressant Drugs
  • NSAIDs
  • Corticosteroids
  • Biological Drugs

According to market experts, biologic therapy is increasingly used to treat autoimmune disorders in developed markets, but usage is still low in emerging markets. Biologic therapies have been acknowledged as effective treatments for various autoimmune diseases. However, the associated costs are high due to complex manufacturing processes. In 2012, a study by the National Institute for Health and Care Excellence (NICE) found that in the U.K., biological drugs cost twenty times as much as conventional therapy. In 2015, chemical-based drugs accounted for the major market share, but during the forecast period, 2016 – 2022, biologic drugs are expected to project significant growth. The key factors assisting the segment growth were enhanced reimbursement policies have increased the use of biological drugs in developed markets, the growing prevalence of autoimmune diseases coupled with growing public awareness, and technological advancements such as the development of novel biomarkers such as Enbrel and Humira.

For this study, the global autoimmune diseases treatment market is categorized into:

  • North America
  • Europe
  • Asia Pacific
  • Rest of the World

North America was observed as the largest market for autoimmune disease treatment in 2015 due to the growing prevalence of several forms of autoimmune disorders and the presence of government initiatives such as the Affordable Care Act and Patient Protection Act. According to the American Autoimmune Related Diseases Association (AARDA), autoimmune disease is one of the top 10 leading causes of death in female children and women in all age groups up to 64 years of age, and AARDA also estimates that around 50 million Americans suffer from autoimmune disease. Europe is expected to be the second largest market due to rising healthcare infrastructure and penetration of new technologies. The dominance of North America and Europe in the autoimmune disease market is attributed to factors like the rising prevalence of autoimmune diseases, increasing investments in R&D, and higher disposable income in these regions. However, factors such as developing health infrastructure, increasing awareness among people about health care, and an aging population will fuel the rapid growth of the autoimmune disease treatment market in the Asia-Pacific region in the near future.  

Frequently Asked Questions:

The market for Autoimmune Diseases Treatment is expected to reach US$ XX Bn in 2022.

The Autoimmune Diseases Treatment market is expected to see significant CAGR growth over the coming years, at XX%.

The report is forecasted from 2016-2022.

The base year of this report is 2021.

Genentech Inc., Bayer AG, Merck & Co., Amgen Inc., Johnson & Johnson Limited are some of the major players in the global market.

Choose License Type
Trusted By
Godaddy
Published Date:  May 2016
Category:  Pharmaceuticals
Report ID:   57842
Report Format:   PDF
Pages:   120
Rating:    4.5 (60)
Delivery Time: 24 Hours to 48 Hours   
Connect With Us
+91-8668442535
24/7 Research Support